

FACSIMILE COVER SHEET

SALIWANCHIK, LLOYD & SALIWANCHIK

A Professional Association

2421 N.W. 41st Street

Suite A-1

Gainesville, FL 32606

Telephone (352) 375-8100

Facsimile (352) 372-5800

OFFICIAL**FAX RECEIVED**

JUN 26 2003


GROUP 1600

The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.

TO: Examiner Shanon A. Foley

COMPANY: U. S. Patent Office, Group Art Unit 1648

FAX NO.: (703) 308-4242

FROM: Jeff Lloyd 

DATE: June 25, 2003

NUMBER OF PAGES (INCLUDING COVER SHEET): 8**MESSAGE:**

Re: Serial No. 09/807,783
FREEZE-DRIED HEPATITIS A ATTENUATED LIVE VACCINE AND ITS STABILIZER
Our Docket No.: CCP-100


Attached hereto is

1. Amendment Under 37 CFR §1.111

If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.

I hereby certify that this paper is being
facsimile transmitted to the Patent and
Trademark Office on 25 JUNE 2003.

AMENDMENT UNDER 37 CFR §1.111
Patent Application
EXAMINING GROUP 1648
Docket No. CCP-100
Serial No. 09/807,783

 #35,589
Jeff Lloyd, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Shanon Foley
Art Unit : 1648
Applicant(s) : Jingye Liu *et al.*
Serial No. : 09/807,783
Filed : April 17, 2001
For : Freeze-Dried Hepatitis A Attenuated Live Vaccine and its Stabilizer

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.111

Sir:

In response to the Office Action mailed March 25, 2003, please amend the application identified above as follows:

In the claims:

1. (previously amended) A stabilized lyophilized hepatitis A live vaccine formulation comprising prophylactically effective titers of live attenuated hepatitis A virus and a stabilizer, wherein said stabilizer is present in the vaccine formulation at a concentration sufficient to stabilize the hepatitis A virus against heat inactivation.

Beantid 2. (original) A stabilized lyophilized hepatitis A vaccine formulation according to claim 1, wherein said live attenuated hepatitis A virus is prepared from the wild-type HAV, strain L-A-I.

3. (previously amended) A stabilized lyophilized hepatitis A live vaccine formulation according to claim 1, wherein said stabilizer for lyophilized live hepatitis A virus comprises human serum albumin or gelatin or both of them; trehalose; at least one amino acid selected from the group consisting of